In Silico Exploration of CD200 as a Therapeutic Target for COVID-19

被引:0
|
作者
Perovic, Vladimir [1 ]
Glisic, Sanja [1 ]
Veljkovic, Milena [2 ]
Paessler, Slobodan [3 ]
Veljkovic, Veljko [4 ]
机构
[1] Univ Belgrade, Inst Nucl Sci VINCA, Lab Bioinformat & Computat Chem, Belgrade 11001, Serbia
[2] Hosp Cerebrovasc Dis Sveti Sava, Dept Clin Lab Med, Belgrade 11000, Serbia
[3] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
[4] Biomed Protect, Galveston, TX 77550 USA
关键词
COVID-19; SARS-CoV-2; variants; vaccine; therapeutic target; CD200; ENVELOPE GLYCOPROTEIN; IMMUNE; DISCOVERY; GP120;
D O I
10.3390/microorganisms12061185
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
SARS-CoV-2, the pathogen causing COVID-19, continues to pose a significant threat to public health and has had major economic implications. Developing safe and effective vaccines and therapies offers a path forward for overcoming the COVID-19 pandemic. The presented study, performed by using the informational spectrum method (ISM), representing an electronic biology-based tool for analysis of protein-protein interactions, identified the highly conserved region of spike protein (SP) from SARS-CoV-2 virus, which is essential for recognition and targeting between the virus and its protein interactors on the target cells. This domain is suggested as a promising target for the drug therapy and vaccines, which could be effective against all currently circulating variants of SARS-CoV-2 viruses. The analysis of the virus/host interaction, performed by the ISM, also revealed OX-2 membrane glycoprotein (CD200) as a possible interactor of SP, which could serve as a novel therapeutic target for COVID-19 disease.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] CD200: A putative therapeutic target in cancer
    Moreaux, Jerome
    Veyrune, Jean Luc
    Reme, Thierry
    De Vos, John
    Klein, Bernard
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 366 (01) : 117 - 122
  • [2] Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?
    Walker, Douglas G.
    Lue, Lih-Fen
    FUTURE NEUROLOGY, 2013, 8 (03) : 321 - 332
  • [3] CD200 is induced by ERK and is a potential therapeutic target in melanoma
    Petermann, Kimberly B.
    Rozenberg, Gabriela I.
    Zedek, Daniel
    Groben, Pamela
    McKinnon, Karen
    Buehler, Christin
    Kim, William Y.
    Shields, Janiel M.
    Penland, Shannon
    Bear, James E.
    Thomas, Nancy E.
    Serody, Jonathan S.
    Sharpless, Norman E.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12): : 3922 - 3929
  • [4] The presence of effector immune cells in human CD200 positive tumor samples supports the CD200 immune checkpoint as a novel therapeutic target
    Hamilton, Mark
    Ji, Rui-Ru
    Arulanandam, Tony
    Barr, Sharon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] CD200: a New Target for Immunotherapy in Hematologic Malignancies
    Brunetti, Lorenzo
    Abate, Giovanna
    Gorrese, Marisa
    Raia, Maddalena
    Pascariello, Caterina
    Scalia, Giulia
    Rotoli, Bruno
    Del Vecchio, Luigi
    BLOOD, 2008, 112 (11) : 566 - 567
  • [6] Is hemolysis a novel therapeutic target in COVID-19?
    Ousaka, Daiki
    Nishibori, Masahiro
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Furin: A Potential Therapeutic Target for COVID-19
    Wu, Canrong
    Zheng, Mengzhu
    Yang, Yueying
    Gu, Xiaoxia
    Yang, Kaiyin
    Li, Mingxue
    Liu, Yang
    Zhang, Qingzhe
    Zhang, Peng
    Wang, Yali
    Wang, Qiqi
    Xu, Yang
    Zhou, Yirong
    Zhang, Yonghui
    Chen, Lixia
    Li, Hua
    ISCIENCE, 2020, 23 (10)
  • [8] FXR AS A NEW THERAPEUTIC TARGET FOR COVID-19
    Brevini, Teresa
    Maes, Mailis
    Webb, Gwilym
    Gelson, William T. H.
    Forrest, Sally
    Mlcochova, Petra
    Dillon, Scott
    Varankar, Sagar
    Darvish-Damavandi, Mahnaz
    Mulcahy, Victoria L.
    Kuc, Rhoda E.
    Williams, Thomas L.
    Galanakis, Vasileios
    Vila-Gonzalez, Marta
    Tysoe, Olivia C.
    Muraro, Daniele
    Crozier, Thomas W.
    Bargehr, Johannes
    Sinha, Sanjay
    Swift, Lisa
    Saeb-Parsy, Kourosh
    Davies, Susan
    Marjot, Thomas
    Barnes, Eleanor
    Lohse, Ansgar W.
    Moon, Andrew
    Barritt, A. Sidney
    Gupta, Ravindra K.
    Baker, Stephen
    Davenport, Anthony P.
    Corbett, Gareth
    Buczacki, Simon J. A.
    Lee, Joo-Hyeon
    Gibbs, Paul
    Butler, Andrew J.
    Watson, Christopher J. E.
    Mells, George F.
    Dougan, Gordon
    Vallier, Ludovic
    Sampaziotis, Fotios
    HEPATOLOGY, 2021, 74 : 318A - 318A
  • [9] Bioflavonoids as potential target inhibitors in COVID-19: An in silico analysis
    Gorla, Uma Sankar
    Rao, Koteswara G. S. N.
    Kulandaivelu, Umasankar
    Alavala, Rajasekhar Reddy
    Das, Subham
    Joseph, Alex
    JOURNAL OF RESEARCH IN PHARMACY, 2021, 25 (06): : 982 - 997
  • [10] Potential herbs as therapeutic agents for COVID-19: In silico studies
    Mehrotra, Nupur
    Khan, Sara A.
    Jadhav, Kaustubh
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2021, 10 : S98 - S110